IBD in 2010: Optimizing treatment and minimizing adverse events

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 2, 2011, Pages 74-76

  De Vroey, Bénédicte ^a   Colombel, Jean Frédéric ^b  

^a Centre hospitalier Jolimont   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; FIBRINOLYTIC AGENT; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; VISILIZUMAB;

BIOLOGICAL THERAPY; CANCER RISK; CHEMOPROPHYLAXIS; CORTICOSTEROID THERAPY; CROHN DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUNG EMBOLISM; LYMPHOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; QUALITY OF LIFE; RISK FACTORS; THROMBOEMBOLISM;

EID: 79751507411     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.218     Document Type: Review

References (10)

1. Plevy, S. et al. A phase i study of visilizumab, a humanised anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133, 1414-1422 (2007). (Pubitemid 350029746)
2. Baumgart, D. C et al. Prospective randomized open-label multicenter phase i/ii dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm. Bowel Dis. 16, 620-629 (2010).
3. Sandborn, W. J. et al. anti-CD3 antibody visilizumab is not effective in patients with ntravenous corticosteroid-refractory ulcerative colitis. Gut 59, 1485-1492 (2010).
4. Colombel, J. F. et al. infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010).
5. Grainge, M. J., West, J. & Card, T. R. venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375, 657-663 (2010).
6. White, R. H. The epidemiology of venous thromboembolism. Circulation 107 (Suppl. 1), i4-i8 (2003). (Pubitemid 41289265)
7. Sokol, H. & Beaugerie, L. inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 58, 1427-1436 (2009).
8. Long, M. D. et al. increased risk for non-melanoma skin cancer in patients with nflammatory bowel disease. Clin. Gastroenterol. Hepatol. 8, 268-274 (2010).
9. Cheent, K. et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J. Crohns Colitis 4, 603-605 (2010).
10. Mahadevan, U. et al. One year newborn outcomes among offspring of women with nflammatory bowel disease: the PianO registry [abstract 764]. Gastroenterology 138 (Suppl. 1), S-106 (2010).